The European Patent Office has granted the Evoke Pharma, Inc. EU patent no. 2376075 for its lead product candidate, EVK-001. This patent is related to formulations used in EVK-001, the company's intranasal delivery formulation of metoclopramide for the treatment of symptoms related to diabetic gastroparesis in women.
EVK-001, currently in a phase 3 clinical trial, is a novel treatment for gastroparesis, which is a disease that can hinder the absorption of oral medications due to symptoms including erratic gastric emptying, as well as nausea and vomiting. Evoke's intranasal formulation is designed to provide reliable and predictable delivery of metoclopramide, the only drug approved by the US Food and Drug Administration (FDA) to treat symptoms associated with gastroparesis, through absorption directly into the blood stream, enabling the drug to avoid a patient's impaired stomach.
Dave Gonyer, R.Ph., president and CEO, stated, "While we continue our efforts to complete the phase 3 clinical trial of EVK-001 and file a New Drug Application (NDA) in the US, this European patent provides additional support and opportunities for the company as we work to offer a safe and effective treatment to gastroparesis patients globally. We are excited about the potential to bring this novel and patented intranasal product to market and help those suffering from this difficult disease."
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases.